Shape Therapeutics logo

Shape Therapeutics

startupfundraising.com

Shape Therapeutics develops programmable RNA medicines that use AI and RNA technology to address genetic causes of disease. Its work includes RNA editing, next-generation AAV delivery and gene therapy manufacturing for pharmaceutical innovators developing treatments for rare genetic disorders and other diseases.

Facts

HQ
Seattle, Washington, US
Sectors
Biotechnology Research
Founded
2018
Type
Corporation Seattle business license
Employees
51–200
Registered name
Shape Therapeutics Inc Seattle business license
Stage
Series B

Is this your organization? Claim it

Shape Therapeutics and Rett Syndrome Research Trust partner to advance SHP-401 AI-designed RNAfix® therapy correcting MECP2 R168X toward IND studies

Shape Therapeutics and the Rett Syndrome Research Trust partnered to fund translational studies of SHP-401, an intravenously delivered, one-time RNAfix® gene therapy using AI-designed guide RNA to correct the MECP2 R168X mutation for Rett syndrome. Preclinical mouse data posted to bioRxiv show ~70% RNA editing in the brain and restoration of full-length MeCP2 after a single IV dose, supporting IND-enabling study goals in non-human primates.

People

  • David Huss Executive, Chief Scientific Officer and Interim CEO
  • Francois Vigneault Former founder

Online